Currently out of the existing stock ratings of Bill Maughan, 28 are a BUY (71.79%), 11 are a HOLD (28.21%).

Bill Maughan

Work Performance Price Targets & Ratings Chart

Analyst Bill Maughan, currently employed at CANACCORD, carries an average stock price target met ratio of 46.9% that have a potential upside of 62.57% achieved within 148 days. Previously, Bill Maughan worked at TD COWEN.

Bill Maughan’s has documented 79 price targets and ratings displayed on 15 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on DNTH, Dianthus Therapeutics at 10-Mar-2026.

Wall Street Analyst Bill Maughan

Analyst best performing recommendations are on THTX (THERATECHNOLOGIES).
The best stock recommendation documented was for THTX (THERATECHNOLOGIES) at 7/3/2023. The price target of $2 was fulfilled within 32 days with a profit of $1.48 (42.53%) receiving and performance score of 13.29.

Average potential price target upside

of $35.07 (23.18%) on KRYS (KRYSTAL BIOTECH).
of $14.78 (72.27%) on BEAM (BEAM THERAPEUTICS ).
of $12.23 (10.43%) on MRNA (MODERNA).

DCTH Delcath Systems FATE Fate Therapeutics IPSC Century Therapeutics NKTX Nkarta IMCR Immunocore Holdings Ltd MRNA Moderna BEAM Beam Therapeutics BNTX BioNTech SE CRSP Crispr Therapeutics AG DNTH Dianthus Therapeutics EDIT Editas Medicine KRYS Krystal Biotech OCUL Ocular Therapeutix THTX Theratechnologies YMAB Y mAbs Therapeutics

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Marie Thibault (BTIG)